In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.
The in vitro and in vivo activities of a new benzoxazinorifamycin, KRM-1648 (KRM), against Mycobacterium tuberculosis were studied. The MIC at which 50% of the isolates are inhibited (MIC50) and the MIC90 of KRM for 30 fresh isolates of M. tuberculosis measured by the BACTEC 460 TB System were 0.016...
Kaydedildi:
| Yayımlandı: | Antimicrob Agents Chemother |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society for Microbiology (ASM)
1995
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC162932/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8619585/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.10.2295 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|